Literature DB >> 6563940

Natural cytotoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK432.

E Yanagawa, A Uchida, M Micksche.   

Abstract

Lymphocytes isolated from axillary lymph nodes draining breast carcinoma were tested for natural killer (NK) activity against K562 in a 4-h 51Cr-release assay, and the in vitro effects of interferon (IFN) and OK432 (a streptococcal preparation) on their cytotoxicity were examined in comparison with NK activity of autologous peripheral blood lymphocytes (PBL). The levels of NK activity were lower in lymph node lymphocytes (LNL) than in PBL of the same patients. Significant levels of LNL-mediated lysis were recorded in 14 of 42 (33%) lymph node samples and in nine of 14 (64%) patients. Purification of large granular lymphocytes (LGL) from lymph node cells by discontinuous Percoll density gradient centrifugation resulted in an induction or enhancement of cytotoxic activity, with no reactivity in LGL-depleted, small T-lymphocyte populations. Positive reactions were observed with 10 of 13 (77%) LGL samples. The low reactivity of LNL was not attributable to coexistent suppressor cells for NK function, since lymph node cells failed to suppress NK activity of normal PBL. Partially purified human IFN and OK432 augmented NK activity of patients' PBL in approximately 70% and 90% of the cases, respectively, while LNL-mediated lysis was augmented in only 7% and 36% of the lymph node samples by IFN and OK432, respectively. These results indicate that K562-reactive NK cells and/or their precursors may frequently be present at subthreshold levels in the lymph nodes draining breast carcinoma, and that the augmentation of LNL-mediated cytotoxicity by OK432 might provide a local potentiation of natural immune function at the host-tumor interface rather than IFN.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6563940     DOI: 10.1007/bf00205490

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

Review 1.  Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets.

Authors:  E Saksela; T Timonen; A Ranki; P Häyry
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium parvum-injected, bone marrow-tolerant, and infant mice.

Authors:  C A Savary; E Lotzová
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  Distribution of natural killer cell activity in peripheral blood, cord blood, thymus, lymph nodes, and spleen and the effect of in vitro treatment with interferon preparation.

Authors:  P Antonelli; W Stewart; B Dupont
Journal:  Clin Immunol Immunopathol       Date:  1981-05

4.  In vitro enhancement of natural and antibody-dependent lymphocyte-mediated cytotoxicity against tumor target cells by interferon.

Authors:  M J Droller; H Borg; P Perlmann
Journal:  Cell Immunol       Date:  1979-10       Impact factor: 4.868

5.  Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease.

Authors:  O Eremin; J Ashby; J P Stephens
Journal:  Int J Cancer       Date:  1978-01-15       Impact factor: 7.396

Review 6.  Do natural killer cells engage in regulated reactions against self to ensure homeostasis?

Authors:  G Cudkowicz; P S Hochman
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

7.  Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions.

Authors:  A Uchida; M Micksche
Journal:  Int J Cancer       Date:  1983-07-15       Impact factor: 7.396

8.  Human natural killer cell activity is augmented by interferon via recruitment of 'pre-NK' cells.

Authors:  E Saksela; T Timonen; K Cantell
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

9.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

10.  Enhancement of human natural cell-mediated cytotoxicity by interferon.

Authors:  M Moore; M R Potter
Journal:  Br J Cancer       Date:  1980-03       Impact factor: 7.640

View more
  6 in total

1.  Natural killer and antibody-dependent cellular cytotoxicity in cervical carcinoma patients.

Authors:  M N Satam; J N Suraiya; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients.

Authors:  E Yanagawa; A Uchida; M Moore; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Effects of the oral or intratumoral administration of OK432 on the immuno-reactivities of regional lymph nodes in gastric cancer patients.

Authors:  E Yanagawa; T Toge; Y Yamaguchi; H Kuninobu; K Kuroi; Y Kegoya; N Baba; T Takayama; Y Sato
Journal:  Jpn J Surg       Date:  1991-05

4.  Interleukin 2 and interferon-gamma activities of mononuclear cells from regional lymph nodes in patients with gastric cancer.

Authors:  K Kusugami; T Matsuura; T Kawase; K Ina; H Matsunaga; Y Kuwahara; T Inagaki; K Morise; K Shimokata
Journal:  Gastroenterol Jpn       Date:  1990-06

5.  The regulation of natural killer cell activity by splenic nonspecific suppressor cells and its modification in cancer patients.

Authors:  E Yanagawa; T Toge; A Sawamura; Y Kegoya; N Baba; T Hattori
Journal:  Jpn J Surg       Date:  1988-11

6.  Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.

Authors:  Yun-Huan Zhen; Xiao-Hui Liu; Yuan Yang; Bo Li; Jing-Ling Tang; Qiang-Xing Zeng; Jie Hu; Xing-Nan Zeng; Lu Zhang; Ze-Jun Wang; Xiao-Yun Li; Hui-Xin Ge; Ola Winqvist; Ping-Sheng Hu; Jin Xiu
Journal:  Cancer Immunol Immunother       Date:  2015-05-20       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.